Maia Biotech wins Spanish, Portuguese regulatory clearance to screen patients in THIO-104 lung cancer trial

• Maia Biotechnology won regulatory clearance in Spain, Portugal to start screening for its Phase 3 THIO-104 NSCLC trial.
• AEMPS, INFARMED authorizations extend the pivotal study’s European footprint ahead of a planned 2027 interim survival analysis.
• Trial enrolled 65 patients to date; target is 100 dosed by year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230917PRIMZONEFULLFEED9831706) on September 23, 2026, and is solely responsible for the information contained therein.